HLA-A*01:01 (AA 25-305), (Monomer) protein (His-Avi Tag,DSG3)

N° du produit ABIN7454252

Cette protéine Recombinant est exprimée dans HEK-293 Cells.

Aperçu rapide pour HLA-A*01:01 (AA 25-305), (Monomer) protein (His-Avi Tag,DSG3) (ABIN7454252)

Antigène: HLA-A*01:01

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Pureté: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Détail du produit

Attributs du protein: AA 25-305, Monomer

Purification/Conjugué: His-Avi Tag,DSG3

Fonction: Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein

Séquence: Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M)and YTDNWLAVY peptide.

Specificité: Uni-Prot: Q5SUL5 (HLA-A*01:01), P61769 (B2M), YTDNWLAVY

Attributs du produit: Recombinant Human HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein is expressed from HEK293 with His tag and Avi Tag at the C-Terminus.It contains Gly25-Thr305(HLA-A*01:01), Ile21-Met119(B2M) and YTDNWLAVY peptide..

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Stock: -20 °C,-80 °C

Stockage commentaire: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Date de péremption: 12 months

Détail du antigène

Antigène: HLA-A*01:01

Sujet: DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.

Poids moléculaire: 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Tris-Bis PAGE result.

UniProt: Q5SUL5